Mucinous (colloid) breast carcinoma is a relatively rare but favorable prognosis invasive breast carcinoma subtype, accounting for 1-7% of all breast cancers. Histologically, tumor cells are found in small clusters 'floating' within large mucin pools — this dense extracellular mucin accumulation determines the imaging characteristics of the tumor. Typically seen in postmenopausal women (60-70 years). Pure mucinous carcinoma presents as a well-circumscribed, round/oval mass on imaging and frequently mimics benign lesions (fibroadenoma, cyst). Demonstrates marked T2 hyperintensity (mucin content) and late progressive enhancement on MRI. It is a low-grade, slow-growing tumor; lymph node metastasis rate is low (2-15%) and 10-year survival rate is above 90%. Mixed mucinous carcinoma (with invasive ductal component) shows a more aggressive course.
Age Range
50-80
Peak Age
65
Gender
Female predominant
Prevalence
Uncommon
Mucinous carcinoma is characterized by excessive mucin production by tumor cells of ductal epithelial origin. Mucin forms a gel-like matrix composed of high molecular weight glycoproteins. MUC2 and MUC6 genes are overexpressed and extracellular mucin accumulation isolates tumor cells as small islands within large pools. This mucin matrix limits the tumor's capacity to invade surrounding tissue — this is the basis for low invasiveness and well-circumscribed growth pattern. Mucin has high water-binding capacity (up to 95% water); this hydrophilic structure forms the physiological basis for marked T2 hyperintensity on MRI — long T2 relaxation time of free water protons. On mammography, the mucin matrix shows soft tissue density but forms a well-circumscribed oval mass because mucin pushes surrounding tissue with a 'cushion' effect rather than invading → pseudocapsule formation. On US, the acoustic impedance of mucin content is close to water → posterior acoustic enhancement (cyst-like). The low cellularity and limited vascularity of the mucin matrix causes slow and low-volume contrast agent accumulation → late, progressive (Type I) enhancement pattern on MRI.
The combination of marked T2 hyperintensity approaching fluid signal with Type I (progressive) enhancement pattern on MRI is the signature finding combination of mucinous breast carcinoma. The coexistence of these two findings in a well-circumscribed breast mass strongly distinguishes mucinous carcinoma from other benign and malignant lesions.
Markedly homogeneous hyperintense signal on T2-weighted images — brightness approaching fluid signal. The high water-binding capacity of the mucin matrix gives the tumor cyst-like T2 signal. This finding is distinctly different from the intermediate-to-low T2 signal seen in most invasive breast carcinomas and is the MRI finding most strongly suggestive of mucinous carcinoma. Pure mucinous type shows homogeneous, mixed type shows heterogeneous T2 signal.
Report Sentence
The mass demonstrates markedly homogeneous hyperintense signal on T2-weighted sequences with brightness approaching fluid signal, consistent with mucin content; this finding strongly suggests mucinous (colloid) breast carcinoma.
Mucinous carcinoma typically demonstrates slow, progressive enhancement pattern (Type I kinetics) on dynamic contrast-enhanced MRI. Early enhancement amplitude is low and increases slowly over time. Rapid early enhancement and washout (Type III) expected in typical malignant lesions is generally not seen. This benign-like kinetic pattern is the fundamental reason why mucinous carcinoma mimics benign lesions on MRI.
Report Sentence
The mass demonstrates slow, progressive enhancement pattern (Type I kinetics) without washout on dynamic contrast-enhanced MRI; this pattern is consistent with mucinous carcinoma but does not exclude malignancy.
A well-circumscribed, oval or round, homogeneous hypoechoic or isoechoic mass is seen on US. The most important US finding is posterior acoustic enhancement — cyst-like transmissivity. Mass margins are sharp and smooth. Shows parallel orientation (wider-than-tall). This appearance can be confused with fibroadenoma or cyst (BI-RADS 3-like). However, a new and growing mass in a postmenopausal woman should be assessed as BI-RADS 4.
Report Sentence
A well-circumscribed, oval, homogeneous hypoechoic mass with posterior acoustic enhancement is seen in the breast parenchyma; despite benign appearance in BI-RADS classification, biopsy is recommended in the postmenopausal context.
A well-circumscribed, round or oval, isodense or slightly low-density mass is seen on mammography. Margins are sharp and spiculated margin, architectural distortion, or microcalcifications are generally absent. A thin 'halo' sign (radiolucent border) surrounding the mass may be visible. This appearance resembles fibroadenoma, cyst, or phyllodes tumor. May be classified as BI-RADS 3 or 4A on mammographic assessment.
Report Sentence
A well-circumscribed, oval, isodense mass is seen on mammography without spiculated margins or microcalcifications; while the appearance is benign, mucinous carcinoma should be included in the differential diagnosis of malignancy in the postmenopausal context.
Mucinous carcinoma shows variable findings on DWI. In pure mucinous type, diffusion restriction may be mild or absent (high water content mucin matrix → low cellularity → ADC values relatively preserved). In mixed mucinous type, more prominent diffusion restriction may be seen in areas of invasive ductal component. ADC values are typically higher than IDC.
Report Sentence
Mild or indeterminate diffusion restriction is seen in the mass on DWI with partially preserved ADC values; this finding may be consistent with low-cellularity mucinous carcinoma.
Criteria
More than 90% of the tumor consists of mucinous component. Sparsely distributed tumor cell clusters within dense mucin pools, not hypercellular.
Distinct Features
Best prognosis. Low grade, low Ki-67. Lymph node metastasis rare (2-4%). ER/PR positive (90%+), HER2 negative. 10-year survival >95%.
Criteria
More than 90% mucinous component but hypercellular variant. Denser tumor cell clusters within mucin pools.
Distinct Features
More aggressive than Type A. May show neuroendocrine differentiation. Lymph node metastasis slightly more common. Prognosis is still better than IDC.
Criteria
Mucinous component <90%, accompanied by invasive ductal carcinoma component. Both histological patterns coexist.
Distinct Features
More aggressive course, higher grade. Higher lymph node metastasis rate (15-20%). More heterogeneous appearance on MRI, Type II/III kinetics possible. Low ADC in IDC component.
Distinguishing Feature
Fibroadenoma can also be T2 hyperintense but enhancement is usually early and prominent (vascular stroma of fibroadenoma). Fibroadenoma typically occurs in young women. Mucinous carcinoma is distinguished by postmenopausal context and ADC difference.
Distinguishing Feature
IDC shows spiculated margins, Type III kinetics (washout), low T2 signal and low ADC. Mucinous carcinoma shows well-circumscribed margins, high T2, Type I kinetics and preserved ADC.
Distinguishing Feature
Simple cyst is anechoic, thin-walled, compressible and meets simple cyst criteria on US. Mucinous carcinoma contains hypoechoic solid component, is not compressible, and yields gelatinous material on aspiration (not fluid).
Urgency
routineManagement
surgicalBiopsy
NeededFollow-up
6-monthMucinous carcinoma requires surgical treatment (lumpectomy or mastectomy). Prognosis is excellent in pure mucinous type (10-year survival >90%). Sentinel lymph node biopsy is performed but axillary metastasis rate is low. Hormonal therapy (ER/PR positive) is applied as adjuvant. Chemotherapy is rarely needed in pure type, standard IDC protocol in mixed type. Annual follow-up with mammography and MRI is recommended.
Mucinous carcinoma is a breast cancer subtype with favorable prognosis. 5-year survival exceeds 90% (in pure mucinous type). High ER/PR positivity, HER2 usually negative. Axillary lymph node metastasis is less frequent. Treatment is surgery + hormonal therapy. Mixed mucinous type has a more aggressive course.